Cefilavancin | CAS#722454-12-8 | antibiotic

MedKoo Cat#: 585241 | Name: Cefilavancin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefilavancin is a glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria.

Chemical Structure

Cefilavancin

CAS#722454-12-8

Theoretical Analysis

MedKoo Cat#: 585241

Name: Cefilavancin

CAS#: 722454-12-8

Chemical Formula: C87H95Cl3N16O28S2

Exact Mass: 1980.5009

Molecular Weight: 1983.27

Elemental Analysis: C, 52.69; H, 4.83; Cl, 5.36; N, 11.30; O, 22.59; S, 3.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Cefilavancin; TD-1792; TD1792; TD 1792

IUPAC/Chemical Name

(6R,7R)-7-[[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[3-[[(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carbonyl]amino]propoxyimino]acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key

OGUAFUAJSPORAH-KHCCTVBNSA-N

InChi Code

InChI=1S/C87H95Cl3N16O28S2/c1-33(2)20-45(94-5)74(117)100-62-66(112)36-11-14-49(43(88)22-36)130-51-24-38-25-52(70(51)134-85-71(69(115)68(114)53(31-107)132-85)133-55-29-87(4,93)72(116)34(3)129-55)131-50-15-12-37(23-44(50)89)67(113)63-81(124)99-59(42-26-40(108)27-48(110)56(42)41-21-35(10-13-47(41)109)57(77(120)101-63)98-78(121)58(38)97-75(118)46(28-54(91)111)96-80(62)123)76(119)95-16-9-19-128-104-61(60-73(90)136-86(92)103-60)79(122)102-64-82(125)106-65(84(126)127)39(32-135-83(64)106)30-105-17-7-6-8-18-105/h6-8,10-15,17-18,21-27,33-34,45-46,53,55,57-59,62-64,66-69,71-72,83,85,94,107,112-116H,9,16,19-20,28-32,93H2,1-5H3,(H15-,91,92,95,96,97,98,99,100,101,102,103,104,108,109,110,111,117,118,119,120,121,122,123,124,126,127)/t34-,45+,46-,53+,55-,57+,58+,59-,62+,63-,64+,66+,67+,68+,69-,71+,72+,83+,85-,87-/m0/s1

SMILES Code

O=C(C(N12)=C(C[N+]3=CC=CC=C3)CS[C@]2([H])[C@H](NC(/C(C4=C(Cl)SC(N)=N4)=N\OCCCNC([C@@H](N5)C6=C(C(O)=CC(O)=C6)C7=C(O)C=CC([C@@]8([H])NC([C@](C9=CC(OC(C=C%10)=C(Cl)C=C%10[C@@H](O)[C@@](NC8=O)([H])C5=O)=C(O[C@@H]%11O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%11O[C@@H]%12O[C@@H](C)[C@@H](O)[C@@](C)(N)C%12)C(OC%13=C(Cl)C=C(C=C%13)[C@@H](O)[C@@H](NC([C@H](NC)CC(C)C)=O)C(N[C@H]%14CC(N)=O)=O)=C9)([H])NC%14=O)=O)=C7)=O)=O)C1=O)[O-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,983.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR; TD-1792 Investigators Group. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Nov;56(11):5476-83. doi: 10.1128/AAC.00712-12. Epub 2012 Aug 6. PubMed PMID: 22869571; PubMed Central PMCID: PMC3486540. 2: Blais J, Lewis SR, Krause KM, Benton BM. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob Agents Chemother. 2012 Mar;56(3):1584-7. doi: 10.1128/AAC.05532-11. Epub 2011 Dec 27. PubMed PMID: 22203585; PubMed Central PMCID: PMC3294951. 3: Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model. Antimicrob Agents Chemother. 2012 Mar;56(3):1578-83. doi: 10.1128/AAC.05382-11. Epub 2011 Dec 12. PubMed PMID: 22155835; PubMed Central PMCID: PMC3294954. 4: Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates. Antimicrob Agents Chemother. 2010 Sep;54(9):3799-803. doi: 10.1128/AAC.00452-10. Epub 2010 Jun 28. PubMed PMID: 20585126; PubMed Central PMCID: PMC2935031. 5: Tyrrell KL, Citron DM, Warren YA, Goldstein EJ. In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob Agents Chemother. 2012 Apr;56(4):2194-7. doi: 10.1128/AAC.06274-11. Epub 2012 Jan 30. PubMed PMID: 22290981; PubMed Central PMCID: PMC3318369. 6: Long DD, Aggen JB, Chinn J, Choi SK, Christensen BG, Fatheree PR, Green D, Hegde SS, Judice JK, Kaniga K, Krause KM, Leadbetter M, Linsell MS, Marquess DG, Moran EJ, Nodwell MB, Pace JL, Trapp SG, Turner SD. Exploring the positional attachment of glycopeptide/beta-lactam heterodimers. J Antibiot (Tokyo). 2008 Oct;61(10):603-14. doi: 10.1038/ja.2008.80. PubMed PMID: 19168974. 7: Turner B, Murch L. Interscience Conference on Antimicrobial Agents and Chemotherapy--49th annual meeting. Part 1. 11-15 September 2009, San Francisco, CA, USA. IDrugs. 2009 Nov;12(11):667-9. PubMed PMID: 19844846.